From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Olgotrelvir (STI-1558) sodium is an orally active dual inhibitor of coronavirus mainprotease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir sodium is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir sodium can effectively inhibit both SARS-CoV-2 replication and entry into host cells .
SARS-CoV-2 Mpro-IN-46 (Compound 12) is a SARS-CoV-2mainprotease inhibitor with an IC50 of ∼25 μM. SARS-CoV-2 Mpro-IN-46 has potent antiviral activity with low cytotoxicity against SARS-CoV-2 (IC50: 7.4 μM). SARS-CoV-2 Mpro-IN-46 can be used for coronaviruses COVID-19 research .
SPR38 is a potent SARS-CoV-2mainprotease inhibitor, with a Ki of 0.260 μM. SPR38 also inhibits hCatL and hCatB, with Ki values of 1.92 μM and 11.1 μM, respectively .
Olgotrelvir (STI-1558) is an orally active dual inhibitor of coronavirus mainprotease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir can effectively inhibit both SARS-CoV-2 replication and entry into host cells .
Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2mainprotease inhibitor with an IC50 of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .
SARS-CoV-2 Mpro-IN-20 (compound MPI100) is a SARS-CoV-2mainprotease inhibitor. SARS-CoV-2 Mpro-IN-20 shows antiviral activity with the EC50 of 3.4 μM .
X77 is a potent non-covalent inhibitor of the mainprotease of SARS-CoV-2(SARS-CoV-2 M pro) . X77 binds to SARS-CoV-2 M pro with a Kd value of 0.057 μM .
MC12 is a thiazole-based derivative and a SARS-CoV-2mainprotease inhibitor (IC50: 77.7 nM). MC12 exhibits inhibitory effects on both SARS-CoV and SARS-CoV-2mainproteases, with low cytotoxicity and good stability. MC12 can be used in the research of anti-COVID-19 drugs .
(Rac)-X77?is a racemate of X77. X77 is a potent non-covalent inhibitor of the mainprotease of SARS-CoV-2(SARS-CoV-2 M pro) . X77 binds to SARS-CoV-2 M pro with a Kd value of 0.057 μM .
SARS-CoV-2-IN-69 (Compound 7E) is a non-covalent SARS-CoV-2 inhibitor with an EC50 value of 7.4 μM. SARS-CoV-2-IN-69 is a potent inhibitor of SARS-CoV-2mainprotease (M pro) and a non-covalent inhibitor of papain (PL pro) .
Mpro/PLPro-IN-2 (Compound 22l) is a non-covalent competitive dual inhibitor of the papain-like protease and mainprotease of SARS-CoV-2, with a Ki of 0.2 μM for the papain-like protease and a Ki of 1.1 μM for the mainprotease . Mpro/PLPro-IN-2 can be used in the research field of anti-SARS-CoV-2 .
SARS-CoV-2 Mpro-IN-5 is a dual Inhibitor of MainProtease (M Pro) and Cathepsin L (CatL), with IC50s of 1800 nM and 145 nM respectively. SARS-CoV-2 Mpro-IN-5 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-5 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 14.7 nM .
SARS-CoV-2 Mpro-IN-4 is a dual Inhibitor of MainProtease (M Pro) and Cathepsin L (CatL), with IC50s of 900 nM and 60 nM respectively. SARS-CoV-2 Mpro-IN-4 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-4 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 8.2 nM .
SPR41 is a potent SARS-CoV-2mainprotease inhibitor with Ki values of 0.184, 0.252, 14.4 µM for SARS-CoV-2 M pro, hCatL, hCatB, respectively. SPR41 shows antiviral and cytotoxicity .
SPR39 is a potent SARS-CoV-2mainprotease inhibitor with Ki values of 0.252, 3.38, 7.88 µM for SARS-CoV-2 M pro, hCatL, hCatB, respectively. SPR39 shows antiviral and cytotoxicity .
SARS-CoV-2 Mpro-IN-29 (Compound 7) is an inhibitor of the SARS-CoV-2mainprotease (Mpro) with an IC50 of 310 nM and an EC50 of 0.5 μM in Vero cells. SARS-CoV-2 Mpro-IN-29 binds to the active site of Mpro, blocking the cleavage of viral polyproteins, showing significant antiviral activity and enhanced metabolic function. SARS-CoV-2 Mpro-IN-29 holds potential for research on SARS-CoV-2 antiviral agents .
SARS-CoV-2 Mpro-IN-21 (compound A8) is a potent SARS-CoV-2 and OVID-19 MainProtease M Pro inhibitor. SARS-CoV-2 Mpro-IN-21 shows excellent antioxidant activity in DPPH assay with an IC50 of 0.36 mg/mL. SARS-CoV-2 Mpro-IN-21 also exhibits better antibacterial potency against Klebsiella with an IC50 of 1.19 mg/mL .
SARS-CoV-2 Mpro-IN-39 (Compound 9d) is an inhibitor of the mainprotease (Mpro) of SARS-CoV-2, with an IC50 value of 5.94 µM, an EC50 value of 9.33 µM for inhibiting the replication of SARS-CoV-2 in Vero cells, and a cytotoxicity CC50 value of 289.63 µM. SARS-CoV-2 Mpro-IN-39 can be used in the research of the anti-COVID-19 field .
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL pro. 3CL pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .
SARS-CoV-2-IN-21 (compound 10), a penicillin sulfone benzyl C6 derivative, is a potent SARS-CoV-2mainprotease inhibitor, with an IC50 of 5.3 μM. SARS-CoV-2-IN-21 can be used for COVID-19 research .
SARS-CoV-2 Mpro-IN-44 (Compound 25) is a broad-spectrum coronavirus mainprotease (Mpro) inhibitor. SARS-CoV-2 Mpro-IN-44 has inhibitory activity against a variety of high-risk coronaviruses (including SARS-CoV-2 and PEDV, etc.) (IC50: < 0.6 μM). SARS-CoV-2 Mpro-IN-44 achieves broad-spectrum inhibition of coronaviruses by enhancing the interaction with the conserved sites of Mpro. SARS-CoV-2 Mpro-IN-44 can be used for anti-coronavirus drug development .
(±)-Alliin (Standard) is the analytical standard of (±)-Alliin. This product is intended for research and analytical applications. (±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the mainprotease of SARS-CoV-2 (Mpro) .
SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2mainprotease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC50 of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC50 of 0.02-0.52 μM .
SARS-CoV-2 Mpro-IN-37 (compound 8r) is a SARS-CoV-2mainprotease (M pro) inhibitor, with an IC50 of 0.0199 μM. SARS-CoV-2 Mpro-IN-37 inhibits SARS-CoV-1 M pro and MERS-CoV M pro with IC50s of 0.00945 and 0.111 μM, respectively. SARS-CoV-2 Mpro-IN-37 displays high antiviral activity in the nanomolar range without showing cellular toxicity .
Leupeptin is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin potently inhibits serine, cysteine and threonine proteases. Leupeptin inhibits M pro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity .
SARS-CoV-2-IN-59 (compound E07), an imidazoline derivative, is a non-peptide small molecule inhibitor of SARS-CoV-2 that targets the mainprotease (Mpro) of the coronavirus. SARS-CoV-2-IN-59 has a strong interaction with residues on Mpro (Met 165, Gln 166, Met 165, His 41, Gln 189) .
SARS-CoV-2 Mpro-IN-43 (Compound 1) is a coronavirus mainprotease (Mpro) inhibitor (IC50: 72 μM). SARS-CoV-2 Mpro-IN-43 interacts with key residues in the active site of Mpro via non-covalent binding, exerting its anti-coronavirus effect. SARS-CoV-2 Mpro-IN-43 exhibits moderate to low cytotoxicity, with CC50 values of 13.24, 41.02, and 42.26 µM in HaCaT, HEK293T, and HepG2 cells, respectively. SARS-CoV-2 Mpro-IN-43 can be used in anti-SARS-CoV-2 research .
SARS-CoV-2-IN-112 (Compound 6f) is an orally active and non-peptidic SARS-CoV-2mainprotease inhibitor with an IC50 of 6.48 μM. SARS-CoV-2-IN-11 has potent antiviral activity with low cytotoxicity against WI-38 cells (IC50: 53.81 μM). SARS-CoV-2-IN-112 can be used for coronaviruses COVID-19 research .
Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits M pro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity .
AB-343 is a selective covalent inhibitor of SARS-CoV-2 M pro, with an IC50 of 8 nM and a Ki of 2.8 nM. AB-343 can effectively inhibit themainproteases of SARS-CoV-2 and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases .
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the mainprotease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the mainprotease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
Koenine is a carbazole alkaloid. It is predicted that Koenine has strong binding affinity and inhibitory ability to SARS-CoV-2mainprotease (M pro), which can be used in the research of anti-novel coronavirus drugs .
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2mainprotease (M pro), with an IC50 of 24 nM for wild-type SARS-CoV-2 M pro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants .
NZ-804 is an orally active inhibitor for SARS-CoV-2mainprotease Mpro with an IC50 of 8.9 nM. NZ-804 inhibits the SARS-CoV-2 replication in HeLa-hACE2 cell with an EC50 of 14 nM. NZ-804 exhibits board-spectrum antiviral activity aganst multiple CoVs. NZ-804 diminishes virus replication in mouse and hamster model .
Bofutrelvir (FB2001) is a SARS-CoV-2mainproteaseM pro inhibitor with an IC50 value of 53 nM and an EC50 value of 0.53 μM. Bofutrelvir exhibits potent antiviral efficacy against several current SARS-CoV-2 variants with EC50 values of 0.26-0.42 μM. Bofutrelvir has an additive antiviral effect when combined with Remdesivir (HY-104077) .
ML2006a4 is an orally active inhibitor for SARS-CoV-2mainprotease (M pro) with IC50 in picomolare value. ML2006a4 is cell permeable and antiviral active, that inhibits replication in SARS-CoV-2 in cells Huh7.5.1-ACE2-TMPRSS2 (Huh7.5.1++) in picomolare level
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M pro with an IC50 value of 72.07 nM. The mainprotease (M pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .
Simeprevir- 13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the mainprotease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
MPD2 is a Cereblon-binding ligand-based PROTAC that degrades MPro, the mainprotease of SARS-CoV-2. MPD2 effectively reduced MPro protein levels in 293T cells in a time-dependent manner (DC50=296 nM). MPD2 exhibited potent antiviral activity against multiple SARS-CoV-2 strains and had enhanced potency against Nirmatrelvir (HY-138687) resistant strains. MPD2 provides a new direction for antiviral drug development against SARS-CoV-2 and other emerging coronavirus pathogens (Sturcture Note:(Blue: Cereblon ligand (HY-14658), Black: linker (HY-W275882)；Red: SARS-CoV-2 MPro Inhibitor MP18 (HY-158763)) .
H117 is a PROTAC target protein ligand that can be used to synthesize PROTAC HP211206 (HY-170598). H117 has competitive binding and inhibition ability on SARS-CoV-2mainprotease (M pro) with an IC50 of 151.3 nM .
HP211206 is a SARS-CoV-2mainprotease (M pro) PROTAC degrader. HP211206 effectively degrades SARS-CoV-2 M pro and its drug-resistant mutants. HP211206 has an IC50 of 181.9 nM and a DC50 of 621 nM for M pro. HP211206 has antiviral activity. (Pink: H117 (HY-170599); Black: linker (HY-B0236); Blue: E3 ligase ligand (HY-41547)) .
Leupeptin (hemisulfate) (Standard) is the analytical standard of Leupeptin (hemisulfate). This product is intended for research and analytical applications. Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits Mpro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity[1][2][3].
Solasurine is a steroidal alkaloid that can be isolated from Solanum surrattence. Solasurine can interact with the C3-like protease (SARS-CoV-2mainprotease) amino acids Phe8, Pro9, Ile152, Tyr154, Pro293, Phe294, Val297, and Arg298 .
PROTAC SARS-CoV-2 Mpro degrader-3 (Compound P2) exhibits antiviral activity through the degradation of the mainprotease (Mpro) of human coronaviruses (HCoVs) (DC50=27 μM). PROTAC SARS-CoV-2 Mpro degrader-3 inhibits the viral replication, with EC50 of 4.6 μM, 4.6 μM, and 0.71 μM, for human coronaviruses HCoV-229E, HCoV-OC43 and SARS-CoV-2, respectively. (Pink: ligand for target protein Mpro ligand 2 (HY-161791); Black: linker (HY-161792); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .
UCI-1 is a SARS-CoV-2mainprotease (M pro) cyclic peptide inhibitor with an IC50 of 160 μM. UCI-1 shows no obvious cytotoxicity at the concentration of inhibiting M pro. UCI-1 can be used in the study of anti-COVID-19 drugs .
Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2mainprotease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .
TKB272 is an orally active and selective antiviral agent targeting the mainprotease (Mpro) of SARS-CoV-2. It effectively blocks the infection and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC50 of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC50 as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC50 of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection .
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2mainprotease (M pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research .
Mpro/Cathepsin L-IN-2 (Compound 1) is a dual irreversible inhibitor of SARS-CoV-2mainprotease (M pro, pIC50=8.61) and human cathepsin L (hCTSL, pIC50=7.64). Mpro/Cathepsin L-IN-2 is promising for research of COVID-19 and other coronavirus infections .
Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2mainprotease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .
Proglumetacin is an orally active and potent cyclo-oxygenase inhibitor. Proglumetacin can inhibits SARS-CoV Mpro (mainprotease of the SARS-CoV-2), with an AC50 of 8.9 μM (activity concentration at half maximal activity). Proglumetacin has anti-inflammatory activity, can be used for inflammation (such as Rheumatoid arthritis, and Allergic air pouch inflammation) research[1][2][3].
SARS-CoV-2-IN-32 (compound 3g) is a COVID-19 inhibitor. SARS-CoV-2-IN-32 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-32 exhibits comparatively high binding affinity (-8.8 Kcal/mole) to COVID-19 mainprotease (M pro) (PDB ID: 6LU7). SARS-CoV-2-IN-32 can be used in studies of cancer and COVID-19 .
SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor. SARS-CoV-2-IN-33 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-33 exhibits comparatively good binding affinity (-8.0 Kcal/mole) to COVID-19 mainprotease (M pro) (PDB ID: 6LU7). SARS-CoV-2-IN-33 can be used in studies of cancer and COVID-19 .
Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2mainprotease (M pro and 3CL pro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19 .
MAT-POS-e194df51-1 is an orally active, non-covalent and non-peptide SARS-CoV-2mainprotease (M pro) inhibitor with an IC50 value of 37nM. MAT-POS-e194df51-1 is cytotoxic with EC50 values of 64 nM and 126 nM in A549-ACE2-TMPRSS2 cells and HeLa -ACE2 cells, respectively .
(Rac)-Z-FA-FMK is the racemate of Z-FA-FMK. (Rac)-Z-FA-FMK is an inhibitor of cathepsin B with a Ki of 1.5 μM. (Rac)-Z-FA-FMK inhibits caspase-2, -3, -6, -7, and -9 with IC50s of 6.147, 15.41, 32.45, 9.077, and 110.7 μM. (Rac)-Z-FA-FMK inhibits the mainprotease of SARS-CoV-2 replication with an IC50 of 11.39 μM. (Rac)-Z-FA-FMK inhibits the increased IL-1β level induced by LPS and NF-κB transactivation in macrophages .
SARS-CoV-2 Mpro-IN-42 (compound C5) is a potent SARS-CoV-2 Mpro inhibitor with an IC50 of 33.6 nM. SARS-CoV-2 Mpro-IN-42 can be used in the study of SARS-CoV-2 .
Tectoquinone (Standard) is the analytical standard of Tectoquinone. This product is intended for research and analytical applications. Tectoquinone (2-Methylanthraquinone) is a SARSCoV-2 mainprotease inhibitor against COVID-19. Tectoquinone exhibits strong mosquito larvicidal activity with the LC50 values of 3.3 and 5.4 μg/ml against A. aegypti and A. albopictus in 24 h, respectively .
Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2mainprotease inhibitor with an IC50 of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .
Leupeptin is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin potently inhibits serine, cysteine and threonine proteases. Leupeptin inhibits M pro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity .
UCI-1 is a SARS-CoV-2mainprotease (M pro) cyclic peptide inhibitor with an IC50 of 160 μM. UCI-1 shows no obvious cytotoxicity at the concentration of inhibiting M pro. UCI-1 can be used in the study of anti-COVID-19 drugs .
Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits M pro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity .
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2mainprotease (M pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research .
(±)-Alliin (Standard) is the analytical standard of (±)-Alliin. This product is intended for research and analytical applications. (±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the mainprotease of SARS-CoV-2 (Mpro) .
Koenine is a carbazole alkaloid. It is predicted that Koenine has strong binding affinity and inhibitory ability to SARS-CoV-2mainprotease (M pro), which can be used in the research of anti-novel coronavirus drugs .
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M pro with an IC50 value of 72.07 nM. The mainprotease (M pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .
Leupeptin (hemisulfate) (Standard) is the analytical standard of Leupeptin (hemisulfate). This product is intended for research and analytical applications. Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits Mpro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity[1][2][3].
Solasurine is a steroidal alkaloid that can be isolated from Solanum surrattence. Solasurine can interact with the C3-like protease (SARS-CoV-2mainprotease) amino acids Phe8, Pro9, Ile152, Tyr154, Pro293, Phe294, Val297, and Arg298 .
SARS-CoV-2 3CLpro/3C-like protease Protein (His-Avi) is the recombinant Virus-derived SARS-CoV-2 3CLpro/3C-like protease protein, expressed by E. coli, with N-His, N-Avi labeled tag.
SARS-CoV-2 3CLpro/3C-like protease Protein (sf9, His) is the recombinant Virus-derived SARS-CoV-2 3CLpro/3C-like protease protein, expressed by Sf9 insect cells, with N-His labeled tag.
SARS-CoV-2 3CLpro/3C-like protease Protein (sf9, His-Avi) is the recombinant Virus-derived SARS-CoV-2 3CLpro/3C-like protease protein, expressed by Sf9 insect cells, with N-His, N-Avi labeled tag.
Simeprevir- 13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the mainprotease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
Inquiry Online
Your information is safe with us. * Required Fields.
